Senolytics: Removal of senescent cells.
In a recent paper, “Paradoxes of Senolytics”, 2018, Blagosklonny writes:
“Senolytics are drugs that extend lifespan and delay some age-related diseases by killing senescent cells…Targeting senescent cells has been shown in animal models to prevent such age-related pathologies as emphysema, lung fibrosis, atherosclerosis, osteoporosis, osteoarthritis, renal disease, intervertebral disc pathology, hepatic steatosis.”
The leading senolytics used are currently Dasatinib, Quercetin, and Fisetin.
Dasatinib is the drug of choice as there are three human clinical studies, excellent results in animal trials, and it is well tolerated.
Quercetin: Used in two of three human studies. All mouse studies with Dasatinib included Quercetin. Effectiveness used alone not shown; but very safe and no serous reported side effects.
Hickson: 2019; First study to show Dasatinib would decrease senescent cells in humans.
Method: Dasatinib in dose of 100 mg plus Quercetin 1000 mg was given orally to individuals with diabetic kidney disease for 3 days. 11 days later the senescent cell burden was measured. The 3 day treatment was well tolerated.
1. Senescent cell in subcutaneous adipose tissue was reduced: 35%, 17%, 62% depending on marker used for senescent cells.
2. macrophages, which are anchored to senescent adipose cells were released and reduced 28%.
3. “Crown-like structures” (dead adipose cells) characteristic of adipose tissue in diabetes and obesity were reduced 86%.
4. Healthy adipocyte progenitors (stem cells) were increased 8%.
5. Senescent epidermal cells were reduced 20% as measured by length and 31% by marker.
6. Circulating SASP factors: IL-1a, -2, -6, -9, MMP -2, -9, -12 (Matrix Metalloproteinases) were significantly lower.
Quercetin when used alone without Dasatinib has many uses and is used for respiratory function, cardiovascular function, anxiety & stress, high blood pressure, high cholesterol, atherosclerosis, insulin resistance, diabetes, gout, allergies, hay fever, asthma, cognitive impairment, eye related disorders including cataracts, stomach ulcers, circulation problems, inflammation of the prostate and skin disorders.
Dasatinib is normally used to treat a certain type cancer. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is in a kinase inhibitor. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
After doing a limited custom compounded run of capsules with a blend of Dasatinib and Quercetin we have decided to stop offering this product due to high costs and limited flexibility to our customers. Instead we are not offering:
Dasatinib 100mg x 30 tablets (made by a 2 billion dollar a year Pharmaceutical company very good quality).
Price for 30 capsules of our D & Q Senolytic Activator is US$366.00 this includes express international shipping at no extra cost.
- The dose we recommend is 100 mg Dasatinib + 2000 mg Fisetin or 2000mg Quercetin.
- Once every 14 days or two weeks.
- You may also choose to use 3 capsules Life Extension, Senolytic Activator with 1 tablet of Dasatinib.
- Once every 14 days or two weeks, this may give better results compared to Fisetin or Quercetin alone.
You will need to purchase your own Fisetin, Quercetin or Life Extension Senolytic Activator.
Please note that due to a high level of sales of this product a 14 day delay in shipping may apply.
Please note that we package Dasatinib in packaging to avoid shipping issues.